Verve Therapeutics, Inc. Stock Price, News & Analysis

Eli Lilly (NYSE: LLY) has successfully completed its tender offer for Verve Therapeutics (NASDAQ: VERV). The offer, which expired on July 23, 2025, consisted of $10.50 per share in cash plus one non-tradable contingent value right (CVR) worth up to $3.00 per share upon achieving specific milestones.

The tender offer saw 49,882,464 shares validly tendered, representing approximately 55.7% of Verve's outstanding shares. All conditions of the offer have been met, and Lilly will promptly pay for all validly tendered shares. The acquisition is expected to be finalized on July 25, 2025.

Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire Verve Therapeutics (Nasdaq: VERV), a clinical-stage biotech company specializing in genetic medicines for cardiovascular disease. The deal values Verve at $10.50 per share in cash ($1.0 billion), plus a CVR worth up to $3.00 per share, potentially reaching $13.50 per share ($1.3 billion total). Verve's lead program, VERVE-102, is a first-in-class in vivo gene editing treatment targeting PCSK9 for cardiovascular disease, designed as a one-time treatment for conditions like heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. The FDA has granted Fast Track designation to VERVE-102, currently in Phase 1b trials. The acquisition price represents a 113% premium to Verve's 30-day volume-weighted average trading price, with the deal expected to close in Q3 2025.

Verve Therapeutics (VERV), a clinical-stage biotech company focused on genetic medicines for cardiovascular disease, has granted equity awards to four new employees. The compensation package includes stock options for 65,000 shares with an exercise price of $4.45 per share (matching closing price on grant date) and 22,000 restricted stock units (RSUs). The stock options have a 10-year term with 25% vesting after one year and the remainder vesting monthly over three years. The RSUs will vest equally over three years starting July 1, 2025. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Rule 5635(c)(4).

Verve Therapeutics (VERV), a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET in Miami. Both events will be available via webcast on the company's website and archived for 30 days.

Verve Therapeutics (VERV) reported promising Q1 2025 results and significant progress in its cardiovascular disease pipeline. The company's lead candidate VERVE-102 showed positive initial data from the Heart-2 Phase 1b trial, achieving a mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg dose cohort. The drug demonstrated a favorable safety profile with no serious adverse events. VERVE-102 received FDA Fast Track designation for hyperlipidemia treatment. The company's second candidate, VERVE-201 targeting ANGPTL3, continues progression in the Pulse-1 Phase 1b trial. Financially, Verve maintains a strong position with $497.1 million in cash and equivalents, providing runway into mid-2027. Q1 2025 saw collaboration revenue of $33.0 million and a net loss of $31.0 million ($0.35 per share).

Verve Therapeutics (VERV), a clinical-stage biotech company focused on genetic medicines for cardiovascular disease, has granted equity awards to seven new employees under its 2024 Inducement Stock Incentive Plan. The grants include:

- Stock options for 134,860 shares at $5.67 per share, vesting over 4 years with 25% after year one and monthly thereafter

- 65,398 restricted stock units (RSUs) vesting equally over three years starting July 1, 2025

These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Verve Therapeutics has announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, a single-dose base editing treatment targeting PCSK9 for cardiovascular disease. The trial included 14 participants with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).

Key findings across three dose cohorts (0.3, 0.45, and 0.6 mg/kg) showed:

• Mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg cohort
• Dose-dependent decreases in blood PCSK9 protein levels
• No treatment-related serious adverse events
• No clinically significant changes in ALT or platelets

The company plans to announce final dose escalation data in H2 2025, initiate Phase 2 trials, and receive Eli Lilly's decision on their PCSK9 program opt-in. Current funding is expected to last until mid-2027.

Verve Therapeutics has received FDA Fast Track designation for VERVE-102, an investigational base editing medicine targeting PCSK9 for treating hyperlipidemia patients with high cardiovascular risk. VERVE-102 is designed as a single-course treatment to permanently deactivate the PCSK9 gene in the liver and reduce LDL-C levels.

The treatment is currently in Phase 1b Heart-2 clinical trial, evaluating safety and tolerability in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). The company plans to announce initial safety and efficacy data from the first three dose cohorts (0.3, 0.45, and 0.6 mg/kg) in Q2 2025.

The Fast Track status may enable more frequent FDA communications and potential Priority Review. Verve plans to report final dose escalation data, deliver the opt-in package to Eli Lilly, and begin Phase 2 trials in H2 2025.

Verve Therapeutics, a clinical-stage cardiovascular genetic medicine company, has announced new equity awards granted to three employees on March 31, 2025. The inducement grants, made under the company's 2024 Inducement Stock Incentive Plan, include:

• Stock options to purchase 50,700 shares at $4.57 per share (closing price on grant date)
• 17,800 restricted stock units (RSUs)

The stock options have a 10-year term with a four-year vesting schedule: 25% vesting after one year, followed by monthly installments over three years. The RSUs will vest equally over three years, starting April 1, 2025. Both grants require continued employment for vesting.